A 68-year-old man with COPD (FEV₁ 35% predicted) presents to the emergency department with a 3-day history of productive cough, fever (38.5°C), and dyspnea. He lives in a nursing home and was hospitalized 2 weeks ago for acute exacerbation of COPD, treated with antibiotics for 5 days. On examination: respiratory rate 28/min, SpO₂ 88% on room air, crackles in the right lower lobe. Chest X-ray shows a new right lower lobe infiltrate. Blood cultures are pending. Sputum Gram stain shows gram-negative rods. What is the most appropriate initial antibiotic regimen?

Explanation

## Clinical Diagnosis: Healthcare-Associated Pneumonia (HCAP) **Key Point:** This patient meets HCAP criteria: recent hospitalization (≤90 days), residence in a long-term care facility, and immunosuppression (severe COPD). HCAP is treated as HAP, not CAP, due to risk of multidrug-resistant (MDR) pathogens. **High-Yield:** HCAP risk factors include: - Hospitalization ≥2 days in past 90 days - Residence in nursing home or long-term care facility - Immunosuppression (COPD FEV₁ <35%, chronic corticosteroids, chemotherapy) - Hemodialysis or IV therapy in past 30 days ### Pathogen Coverage HCAP/HAP requires broad-spectrum coverage for: - Pseudomonas aeruginosa (gram-negative rod on Gram stain) - MRSA (if risk factors present) - Other gram-negative organisms (Klebsiella, Acinetobacter) ### Antibiotic Regimen **Empiric therapy for HCAP/HAP:** | Agent | Spectrum | Role | |-------|----------|------| | Piperacillin-tazobactam (4.5 g IV Q6H) | Pseudomonas + anaerobes | First-line | | Ceftazidime (2 g IV Q8H) | Pseudomonas | Alternative | | Fluoroquinolone (levofloxacin 750 mg IV daily) | Atypical + gram-negatives | Add for enhanced coverage | | Vancomycin or linezolid | MRSA | Add if MRSA risk or sepsis | **Clinical Pearl:** Gram-negative rods in sputum + recent hospitalization = assume Pseudomonas until proven otherwise. Monotherapy with beta-lactams or fluoroquinolones alone is inadequate for HAP/HCAP. **Tip:** Duration: 7–8 days for HAP (shorter than CAP). De-escalate based on culture results and clinical response. [cite:Harrison 21e Ch 297]